ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1431	National Cancer Institute	Html	en	Prostate Cancer Prevention (PDQ®)–Patient Version	Expert-reviewed information summary about factors that may influence the risk of developing prostate cancer and about research aimed at the prevention of this disease.	cancer risk factors 0.382888 cancer treatment 0.345379 cancer prevention trials 0.393424 prostate cancer prevention 0.528023 cancer protective factor 0.370188 prostate gland 0.401353 Prostate Cancer Events 0.438643 protective factors 0.37428 Cancer Information Service 0.363767 following PDQ summaries 0.363098 PDQ cancer information 0.439164 advanced prostate cancer 0.435515 high-grade prostate cancer 0.447263 Clinical Trials section 0.34275 prevention clinical trials 0.365763 male sex 0.35549 white men 0.343088 men 0.418793 Prevention Editorial Board 0.367822 treatment clinical trials 0.342421 National Cancer Institute 0.410797 clinical trials 0.465084 folic acid 0.367544	cancer information summary 0.404534 fewer prostate cancers 0.434955 Vitamin E Cancer 0.36527 new treatment 0.346999 localized prostate cancer 0.435368 breast cancer prevention 0.361722 Cancer Prevention Trial 0.41435 prostate cancer increases 0.444676 prostate cancer risk 0.48237 cancer patients 0.343751 Cancer Care page 0.358977 cancer risk factor 0.385548 NCI’s PDQ 0.343309 normal prostate growth 0.414243 PDQ summary 0.356651 aggressive prostate cancers 0.429295 NCI PDQ cancer 0.383175 prostate cancer 0.982122 bigger prostate 0.40149 cancer clinical trials 0.368698 risk factors 0.422068 cancer information summaries 0.367063 comprehensive cancer information 0.367142	CLICK HERE
1650	National Cancer Institute	Html	en	Selected Vegetables/Sun's Soup (PDQ®)–Patient Version	Expert-reviewed information summary about the use of selected vegetables/Sun's soup as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only.	treatment 0.620935 cancer treatment 0.517212 cancer prevention 0.486935 Complementary Therapies Editorial 0.534234 United States 0.494682 Well-designed clinical trials 0.477309 Drug Administration 0.522277 Cancer Information Specialist 0.498157 cancer cells 0.558873 Cancer Information Service 0.567973 PDQ cancer information 0.645069 Cancer Complementary 0.510973 PDQ Selected Vegetables/Sun 0.52487 Vegetables/Sun’s Soup 0.718967 CAM therapies 0.498393 Soup ingredients 0.49536 treatment clinical trials 0.493338 National Cancer Institute 0.676034 clinical trials 0.788657 alternative medicine 0.562862 standard food 0.487423 conventional treatment 0.48119 cancer information summary 0.571239 alternative cancer therapies 0.505071	Federal Trade Commission 0.49349 National Institutes 0.486354 clinical trial 0.532528 new treatment 0.541852 mung bean 0.494966 CAM cancer research 0.493212 breast cancer prevention 0.484457 shiitake mushroom 0.517658 patients 0.594168 cancer patients 0.547142 new treatment works 0.477537 Cancer Care page 0.486585 health 0.482953 Selected Vegetables/Sun 0.982781 PDQ summary 0.47773 non-small cell lung 0.519358 NCI PDQ cancer 0.530378 cancer information database 0.505237 cell lung cancer 0.547396 alternative therapies 0.532329 cancer information summaries 0.505491 Frozen Selected Vegetables 0.492972 Therapies Editorial Board 0.515019	CLICK HERE
1983	National Cancer Institute	Html	es	Tratamiento de los tumores embrionarios del sistema nervioso central infantil (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del meduloblastoma infantil, los tumores embrionarios distintos del meduloblastoma y los tumores pineales infantiles.	meduloblastoma wnt 0.448042 primitive neuroectodermal tumors 0.463972 Kool M 0.408951 tumores wnt 0.418547 prognostic factors 0.423834 germline mutations 0.4087 with medulloblastoma harboring 0.411601 with medulloblastoma receiving 0.411471 early childhood medulloblastoma 0.42493 childhood medulloblastoma 0.434401 meduloblastomas shh 0.413706 Rutkowski S 0.412968 Clin Pract Oncol 0.409953 with carboplatin 0.411606 with localized medulloblastoma 0.410611 Natl Cancer Inst 0.412552 vía wnt 0.411172 with retinoblastoma during 0.417144 Medulloblastoma with extensive 0.410624 Acta Neuropathol 0.421932 Boyett JM 0.420388 Children's Cancer 0.444511 Lancet Oncol 0.408704 medulloblastoma subtypes with 0.411732 subtipo shh 0.409562	meduloblastomas wnt 0.413294 Remke M 0.416131 tumores shh 0.419097 Neuro Oncol 0.413263 Pediatr Blood Cancer 0.465506 Childrens Cancer Group 0.412973 neuroectodermal tumors treated 0.41729 with medulloblastoma 0.429537 Med Genet 0.409674 Clin Oncol 0.618048 sistema nervioso central 0.455844 with supratentorial primitive 0.416554 pediatric medulloblastoma 0.410979 Children's Cancer Group 0.43162 von hoff k 0.413579 tumors treated with 0.41728 término tumor 0.409479 tumores embrionarios 0.947028 Kingdom Children Cancer 0.420872 vía shh 0.424313 children's oncology group 0.440874 Children's Cancer Study 0.422483 molecular subgroups 0.410404 Cancer Study Group 0.41491	CLICK HERE
3453	National Cancer Institute	Html	es	Planificar la transición para la atención del cáncer avanzado en la etapa final de la vida (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre la preparación necesaria por parte de los proveedores de atención de la salud, los pacientes y sus familias para la transición a la atención del cáncer avanzado en la etapa final de la vida.	health care spending 0.331274 Zimmermann C 0.347816 Burman D 0.32527 posibles factores 0.333049 Ewer MS 0.322761 cancer care near 0.391306 creciente número 0.323261 Sin embargo 0.941022 American Cancer Society 0.434589 etapa efv 0.333862 Health Care Brief 0.329424 fase ii 0.322051 Swami N 0.348223 care providers 0.323463 intensive care unit 0.365314 Cancer Care Outcomes 0.349727 coping with cancer 0.340049 quimioterapia paliativa 0.367064 cancer care 0.411213 Early palliative care 0.33009 Landrum MB 0.323564 Dartmouth Institute 0.324797 Estados Unidos 0.323783 Support Care 0.43154 mayores gastos 0.34678	Med Care 0.326126 patients with 0.439314 end-of-life care 0.465368 good death 0.325189 Care Cancer 0.418414 Cancer Facts 0.334548 fase i 0.325785 palliative care 0.349857 cardiac arrest 0.325245 Dartmouth Atlas 0.325161 ill patients with 0.328355 cardiopulmonary resuscitation 0.351378 medical intensive care 0.329231 care intensity 0.323054 beneficiaries dying with 0.321915 Clinical Practice 0.32872 forma favorable calidad 0.324109 alta calidad 0.387852 Health Policy 0.327199 health care 0.342416 Intern Med 0.355877 Clin Oncol 0.402042 Arch Intern Med 0.354168 respiración mecánica 0.42963	CLICK HERE
3456	National Cancer Institute	Html	es	Acupuntura (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos sobre la acupuntura como tratamiento para las personas con cáncer o trastornos relacionados con esta enfermedad.	acupuntura forma 0.644774 Centro Nacional 0.425173 causa reacciones 0.422733 New Hampshire Avenue 0.41766 acupuntos correctos 0.426568 causa hinchazón 0.417784 Drug Administration 0.410869 neuropatía periférica 0.548649 NCI Best Case 0.428652 datos bibliográficos pubmed 0.418907 largo plazo 0.414083 National Cancer Institute 0.420958 siglo xviii 0.41833 siguientes riesgos 0.413128 PDQ Acupuntura 0.568448 acupuntura ayuda 0.53948 Instituto Nacional 0.496395 numerosos informes 0.41497 National Certification Commission 0.424144 Salud Complementaria 0.436282 Visuals Online 0.412814	náuseas matutinas 0.436773 mamaEl linfedema 0.418357 complementarias revisa 0.41658 sistema nervioso central 0.511178 Physician Data Query 0.473664 Medicina Oriental 0.41709 Estados Unidos 0.901304 Comisión Nacional 0.410413 libre uso 0.418723 Oriental Medicine 0.412484 distintos resultados 0.413109 cabo estudios 0.47129 piel agujas 0.436066 página manejo 0.412054 ¿El tratamiento 0.424697 ¿Los beneficios 0.410887 juntos cam 0.410417 qi causa dolor 0.459263 Series Program 0.410794 medicina complementaria 0.788071 Institutos Nacionales 0.521236	CLICK HERE
3519	National Cancer Institute	Html	en	Research Team Members	Information about the different types of experts involved in designing and running a clinical trial.	treatment 0.240173 Typical team members 0.477277 data management 0.339957 records 0.222317 Staff physician 0.322575 concept 0.2227 aspects 0.224933 Institutional Review Board 0.455886 study monitoring 0.329306 Treats patients 0.324814 skills 0.22687 presentation 0.223824 Supervises data collection 0.479065 responsibilities 0.228481 recruitment 0.225467 course 0.246736 health care providers 0.443729 Works 0.240321 audits 0.222243	research nurse 0.569926 final data analysis 0.435286 clinical trial 0.945844 Provides data 0.334954 approval 0.227398 different sites 0.354975 monitoring agencies 0.324055 Assesses 0.227864 Data manager 0.339195 different types 0.351452 Communicates 0.231534 principal investigator 0.901171 person 0.339796 quality assurance 0.332626 Educates staff 0.334468 IRB 0.235474 Designing 0.224461 informed consent process 0.715664 experts 0.226806	CLICK HERE
3935	National Cancer Institute	Html	es	Cáncer recurrente: cáncer que regresa	El cáncer puede regresar cuando el tratamiento no elimina o destruye por completo todas las células cancerosas. Aprenda acerca de los diferentes tipos de recurrencia -recidiva- y cómo se vuelve a asignar un estadio al cáncer y se da tratamiento.			CLICK HERE
4394	National Cancer Institute	Html	null	Blue Ribbon Panel Working Groups	Seven working groups comprised of leading experts from the cancer community have been charged with developing recommendations for the Cancer Moonshot Initiative.			CLICK HERE
16711	National Cancer Institute	Html	null	Iniciativa de Respuestas Excepcionales: Preguntas y respuestas	El Instituto Nacional del Cáncer (NCI) emprendió la Iniciativa de Respuestas Excepcionales a fin de entender la base molecular de los tumores en pacientes de cáncer que responden en forma excepcional al tratamiento, principalmente quimioterapia.			CLICK HERE
16846	National Cancer Institute	Html	en	The University of Texas MD Anderson Cancer Center—Targeted Therapeutics for Ovarian Cancer and its Microenvironment – Treatment and Theoretical Modeling	Will offer nanotherapeutic formulations and novel approaches targeting multiple components of the tumor and its microenvironment, specifically for high-grade serous ovarian cancers.	Anil Sood 0.374281 critical molecular targets 0.456713 significant role 0.350306 ovarian cancer models 0.573698 Gabriel Lopez-Berestein 0.357257 monocyte-macrophage axis 0.343069 dual effect nanoparticles 0.489182 tumor-associated macrophages 0.355321 tumor microenvironment interactions 0.655973 significant antitumor activity 0.470227 five-year mortality rates 0.488005 AXL aptamers 0.532934 AXL-receptor binding aptamers 0.494135 specific AXL aptamers 0.512408 eventual tumor growth 0.616726 ovarian cancer 0.98899 gene silencing molecules 0.467313 current regimens 0.384525 Lokesh sRao 0.372622 Principal Investigators 0.351287 therapeutic nanoparticles 0.389578 maximal anti-tumor efficacy 0.546141 tumor progression 0.503786 Vittorio Cristini 0.380084 therapeutic efficacy 0.513726	Zhihui Wang 0.359239 nanoparticle surface 0.346896 nanoparticle effects 0.34271 drug resistance 0.343585 Sunila Pradeep 0.383374 tumor-promoting TAMs 0.351562 slow-release dual assembly 0.461875 MMA cell accumulation 0.438136 particularly attractive approach 0.453092 deadliest gynecological cancer 0.510101 tumor growth 0.640954 tumor cells 0.528853 David Volk 0.359179 platinum/taxane-based regimens 0.397302 optimal dosing regimens 0.492748 efficacy profiles 0.393175 high mortality rates 0.477298 multipronged dosing schedules 0.45156 Bulent Ozpolat 0.372014 slow release DANPs 0.440473 Traditional therapy 0.34917 serous ovarian cancer 0.612409 cancer biology 0.356075 tumor microenvironment 0.813294	CLICK HERE